Sarcoma and Cutaneous Tumors Science Highlights

This session highlights five of the most clinically relevant abstracts within the Sarcoma and Cutaneous Tumors track of the 2022 ASTRO Annual Meeting Scientific Program. These noteworthy scientific abstracts share important findings and feature cutting edge research from leaders in the field. The Discussant compares and contrasts the current data to help you digest the latest science; places the study into context; and describes how the study can be put into clinical practice, if recommended. 
Highlighted Abstracts include – 

  • Thirteen Years with Preoperative 5x5 Gy in Soft Tissue Sarcomas: A Pattern of Local Failure 
  • Prospective Single-arm Trial of Preoperative 42.75 Gy in 15 Fractions for Soft Tissue Sarcoma of the Extremity/Trunk
  • Stereotactic Ablative Radiation Therapy for Sarcoma Lung Metastases: Indications for Treatment and Patterns of Failure 
  • Role of Adjuvant Regional Nodal Irradiation in Resected Melanoma: A Secondary Analysis of SWOG S1404 
  • Innovative Widefield Volumetric Arc Radiation Therapy (VMAT) Approach to Simultaneously Treat Extensive Skin Field Cancerization (ESFC) + In-field Keratinocyte Carcinoma (KC) in Australian Patients: Report with 12 Month Follow-up 

This activity is available from July 31, 2023, through 11:59 p.m. Eastern time on December 31, 2023. 

This activity was originally recorded at ASTRO’s 2022 Annual Meeting.

Target Audience

The activity is designed to meet the interests of radiation oncologists, radiation oncology residents, physicists and radiation dosimetrists. 


Learning Objectives

Upon completion of this activity, participants:

  • Have had the opportunity to increase knowledge of clinical trials of outcomes when using hypofractionated radiation therapy for extremity soft tissue sarcoma 
  • Gain knowledge of the use and technique of radiation therapy for skin cancers 
  • When appropriate, implement the advances in radiation oncology that help improve patient outcomes and quality of life. 
Course summary
Available credit: 
  • 0.50 Certificate of Attendance
    This activity was designated for 0.50 AMA PRA Category 1 Credit™.
Course opens: 
Course expires: 

Discussant: David Kirsch, MD, PhD, FASTRO, Duke University 

  • Co-founder of XRAD Therapeutics, which is commercializing radiosensitizers 
  • On the Scientific Advisory Board and own stock in Lumicell, which is commercializing intraoperative imaging technology
  • Research support from the NIH (NCI, NIAID, NIA), Department of Defense, Bristol Myers Squibb, XRAD Therapeutics, and Varian Medical Systems 

The person(s) above served as the developer(s) of this activity. Additionally, the Education Committee had control over the content of this activity. All relevant relationships have been mitigated.

The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.

ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification. 

Available Credit

  • 0.50 Certificate of Attendance
    This activity was designated for 0.50 AMA PRA Category 1 Credit™.


Please login or register to take this course.

Course Fees:
ASTRO members must log in to the ASTRO website to view and receive the free member rate.

Nonmember: $79
Member: Free 

No refunds, extensions, or substitutions will be made for those participants who, for any reason, have not completed the course by the end of the qualification date. The qualification date for each course is listed in the course catalog on the ASTRO website under availability.

Participants using ASTRO's online courses to satisfy the requirement of a Maintenance of Certification (MOC) program should verify the number, type and availability dates of any course before making a purchase. No refunds, extensions, or substitutions will be made for participants who have purchased courses that do not align with their MOC requirement.

The course and its materials will only be available on the ASTRO website until December 31, 2023, regardless of purchase date. At the expiration of the qualification, participants will no longer have access to the course or its materials. ASTRO reserves the right to remove a course before the end of its qualification period.

Required Hardware/software

One of the two latest versions of Google Chrome, Mozilla Firefox, Internet Explorer or Safari.